一线EGFRExon20ins：伏美替尼初步疗效数据优异（非头对头对比）

数据来源：2023 ASCO，2024 ASCO，2023 WCLC，《Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial - PubMed》，《Amivantamab in EGFR Exon 20 Insertion– Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study》，《Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer》，国泰君安证券研究